Piramal Pharma's FY2026 Annual Report showcases global scale, innovation-led growth and sustainability milestones

Mumbai, India, July 7, 2026 - Piramal Pharma Limited (PPL) (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, released its Annual Report for FY2026, highlighting a year of strengthening its global platform, investing in differentiated capabilities, advancing sustainability, and delivering quality across operations. The report reflects Piramal Pharma's continued commitment to improving patient outcomes through science-led innovation, operational excellence and quality, while building a resilient global platform that serves customers across regulated markets worldwide.

During FY2026, Piramal Pharma reported revenue from operations of **₹8,869 crore**, supported by a diversified business model with 17 global development and manufacturing facilities, commercial presence across more than 100 countries. Approximately **66% of the Company's revenue was generated from regulated markets**, reinforcing its strong global footprint.

Ms. Nandini Piramal, Chairperson of Piramal Pharma Limited said, *"FY2026 was a transitional year, shaped by external disruptions and certain business-specific factors. Despite these challenges, we exited the year on a stronger note across three businesses with improved execution and better visibility of future growth."*

Key Highlights from the report:

- Piramal Pharma Solutions (CDMO), which contributed **55% of the Company's revenue**, continued to strengthen its position as a leading integrated global CDMO, supporting **over 500 global customers** across the pharmaceutical and biotechnology ecosystem. During the year, the Company also continued strategic investments, including a commitment of **US$90 million expansion** in sterile injectables and payload linker capabilities

- Piramal Critical Care (CHG) further strengthened its leadership in US inhaled anesthesia market, retaining its **No. 1 position in the US Sevoflurane market. Further, it completed the acquisition** of Kenalog, while continuing to serve **over 6,000 hospitals, surgical centres and clinics globally**.

- Piramal Consumer Healthcare delivered **₹1,274 crore** in revenue and continued to strengthen its portfolio of over **25 consumer brands**. The business launched **31 new products and SKUs** during FY2026, while its Power Brands recorded **24% growth**, contributing **52% of overall Consumer Healthcare revenue**

- Quality remained a cornerstone of the Company's operations. During FY2026, Piramal Pharma successfully completed **38 regulatory inspections, including three USFDA inspections. We continue to maintain our status of zero Official Action Indicated (OAI) observations across all USFDA inspections**, reinforcing the strength of PPL's quality systems and compliance standards

- The Company also continued to advance its sustainability agenda, achieving a **22.6% reduction in Scope 1 and Scope 2 greenhouse gas emissions compared with the FY2022 baseline**, following the approval of its science-based decarbonisation roadmap

- Piramal Pharma continued to strengthen its people first culture, with a global workforce of **over 7,285 employees**, while maintaining its strong commitment to workplace safety by achieving **zero fatalities for the fifth consecutive year**

For additional business highlights and key performance metrics, please refer to the accompanying FY2026 infographic.

For more information, please refer to the full report available at https://ppl-da-website-new-afd-endpoint-bgd4d0c9egf9g2eq.a01.azurefd.net/media/documents/Annual-Report-FY-2025-26.pdf

---

About Piramal Pharma Limited

Piramal Pharma Limited (PPL, NSE: PPLPHARMA I BSE: 543635), offers a portfolio of differentiated products and services through its 17[1] global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and Piramal Consumer Healthcare business, selling wellness products across consumer healthcare categories. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments.

For more information, visit: Piramal Pharma | LinkedIn

* Includes one facility via PPL’s minority investment in Yapan Bio.

For Investor Queries:
Gagan Borana
Investor Relations & Enterprise Risk Management
gagan.borana@piramal.com

For Media Queries:
Madiha Vahid
Lead – Branding & Communications
madiha.vahid@piramal.com